Compare GameStop Corp. (GME) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Organon & Co. Common Stock — how do they compare? GameStop Corp. trades at $26.6 (market cap $13.70B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: GameStop Corp. is far larger — about 3.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Organon & Co. Common Stock for 0 Days on average.
| GME | OGN | |
|---|---|---|
Market Cap | $13.70B | $3.61B |
Volume | 16,349,771 | 1,808,049 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $13.81 |
52-Week Low | $17.87 | $5.70 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $12.97B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.22, down slightly by 0.04% on the day. The stock shows strong technical momentum with bullish moving averages and positive price action near resistance at $28. Fundamentally, the company reported net income of $131.3 million in 2025 with improving profit margins of 25.16%, though revenue declined to $3.82 billion. Recent insider buying by CEO Ryan Cohen and directors has driven positive sentiment, with multiple purchases totaling over $26 million in September 2026.
GME presents a mixed outlook with strong insider confidence but challenging fundamentals. The investment opportunity lies in continued operational turnaround and potential strategic moves, while risks include revenue declines, competitive pressures in retail gaming, and the stock's meme stock volatility. Analyst consensus remains cautious with only 16.7% buy ratings versus 27.8% sells.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
